Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CEL-110
- Development stage
- Preclinical
- Lead developer
- Celista Pharmaceuticals
- Modality
- Small Molecules
01
Overview
CEL-110 is a small molecule therapeutic candidate being developed by Celista Pharmaceuticals for the treatment of vasomotor symptoms (VMS), such as hot flashes and night sweats associated with menopause. The drug utilizes an already approved small molecule that is being repurposed for this new indication. CEL-110 is delivered using Celista's proprietary device and formulation technologies, which are designed to optimize the pharmacokinetic profile and improve patient outcomes compared to existing therapies. By leveraging drug repositioning and advanced delivery systems, Celista aims to provide a safer or more effective non-hormonal treatment option for VMS.
Beyond the preview
Go deeper on CEL-110.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CEL-110.